COMMUNIQUÉS West-GlobeNewswire

Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
25/08/2025
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, [...]
OrthoPediatrics Corp. Announces the Appointment of Kelly Fischer to its Board of Directors
25/08/2025
WARSAW, Ind., Aug. 25, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
RxSight, Inc. to Present at the Morgan Stanley Healthcare Conference
25/08/2025
ALISO VIEJO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Option Care Health To Participate in Upcoming Investor Conferences
25/08/2025
BANNOCKBURN, Ill., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will [...]
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
25/08/2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients [...]
Memgen Announces First Patient Dosed in Phase 1 Combination Cohort of MEM-288 Plus Docetaxel in Advanced Non–Small Cell Lung Cancer
25/08/2025
Study designed to assess safety and antitumor activity; data intended to inform a planned randomized Phase 2 study TAMPA, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Memgen, Inc., a clinical-stage biotechnology company [...]
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway
25/08/2025
- U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 2025 HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, [...]
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
25/08/2025
PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the [...]
Hydreight Achieves 33% YoY H1 Revenue Growth, Records 3rd Consecutive Quarter of Profitability, and Strengthens Performance Across Verticals
26/08/2025
“We had a great first 6 months, with 33% year-over-year growth. We have also exceeded our internal metrics across all verticals in the first seven months of the year, reinforcing the strength of our strategy. A key [...]
Protéger le personnel de la santé, c’est nous protéger tous
25/08/2025
Une coalition canadienne obtient un appui massif en faveur des mesures de protection renforcées pour les travailleurs de la santé, prévues dans la mise à jour de la norme sur les appareils de protection respiratoire de [...]
Protecting healthcare workers protects us all:
25/08/2025
Canadian coalition gets overwhelming support backing stronger protections for healthcare workers in updated CSA respirator standard TORONTO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Canadian healthcare workers deserve the same [...]
Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
25/08/2025
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D. The facility will create more than 1,900 jobs and support the production of next-generation metabolic [...]
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
25/08/2025
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its [...]
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
25/08/2025
HOUSTON, TX, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on September 9, 2025, at 4:15 p.m. ET. Attendees will [...]
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
25/08/2025
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other [...]
Husband Material Ministries Announces New Book by Drew Boa: "Outgrow Porn: Find Lasting Freedom Without Fighting an Exhausting Battle—A Man's Guide to Healing"
25/08/2025
Empowering Men to Overcome Pornography Addiction Colorado Springs, CO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Husband Material Ministries , a leading nonprofit organization dedicated to helping men find lasting freedom from [...]
Baylor Genetics to Showcase RNA Sequencing Breakthroughs for Rare Disease Diagnosis at 2025 AGBT Precision Health Meeting
25/08/2025
Company to Highlight the Role of Precision Diagnostics in Transforming Rare and Undiagnosed Disease Care HOUSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of [...]
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
25/08/2025
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure [...]
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
25/08/2025
Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics [...]

Pages